Quest Diagnostics (DGX) Tops Q2 EPS by 12c; Raises Outlook
Tweet
Share
E-mail
Get Alerts DGX Hot Sheet
Price: $246.72 -0.3%
Revenue Growth %: +7.8%
Financial Fact:
Operating income: 322M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +7.8%
Financial Fact:
Operating income: 322M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.36, $0.12 better than the analyst estimate of $2.24. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.32 billion.
GUIDANCE:
Quest Diagnostics sees FY2022 EPS of $9.55-$9.95, versus the consensus of $9.33.
For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Nucor projects Q3 2026 earnings above prior year, below estimates
- Barclays says AI trade is maturing, favors greater diversification
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
